DDAH: A target for vascular therapy?

Aird WC Endothelial biomedicine. New York, NY: Cambridge University Press, 2007.

Cooke JP Flow, NO, and atherogenesis. Proc Natl Acad Sci USA 2003; 100: 768-770.

Schachinger V. , Britten MB , Zeiher AM Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-1906.

Valkonen VP , Paiva H. , Salonen JT , et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127-2128.

Böger RH , Sullivan LM , Schwedhelm E. , et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009; 119: 1592-1600.

Vallance P. , Leone A. , Calver A. , et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575.

Torondel B. , Nandi M. , Kelly P. , Wojciak-Stothard B. , Fleming I. , Leiper J. Adenoviral mediated overexpression of DDAH improves vascular tone regulation. Vasc Med 2010. Online ahead of print publication: 10.1177/1358863X09360264.

Cooke JP Asymmetrical dimethylarginine: The Uber marker? Circulation 2004; 109: 1813-1818.

Teerlink T. ADMA metabolism and clearance. Vasc Med 2005 ; 10(suppl 1): S73-81.

MacAllister RJ , Parry H. , Kimoto M. , et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996; 119: 1533-1540.

Leiper J. , Nandi M. , Torondel B. , et al. Disruption of methyl-arginine metabolism impairs vascular homeostasis . Nat Med 2007; 13: 198-203.

Dayoub H. , Achan V. , Adimoolam S. , et al. DDAH regulates NO synthesis: genetic and physiological evidence . Circulation 2003; 108: 1043-1048.

Jacobi J. , Sydow K. , von Degenfeld G. , et al. Overexpression of dimethylarginine dimethylaminohydrolase (DDAH) reduces tissue ADMA levels and enhances angiogenesis. Circulation 2005; 111: 1431-1438.

Pope AJ , Karrupiah K. , Kearns PN , Xia Y. , Cardounel AJ Role of dimethylarginine dimethylaminohydrolases in the regulation of endothelial nitric oxide production. J Biol Chem 2009; 284: 33,338-35,347.

Boger RH , Bode-Boger SM , Szuba A. , et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842-1847.

Abbasi F. , Asagmi T. , Cooke JP , et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001; 88: 1201-1203.

Stuhlinger MC , Oka RK , Graf EE , et al Endothelial dysfunction induced by hyperhomocysteinemia: role of ADMA. Circulation 2003; 108: 933-938.

Kielstein JT , Zoccali C. Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens 2008; 17: 609-615.

Murray-Rust J. , Leiper J. , McAlister M. , et al. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase . Nat Struct Biol 2001; 8: 679-683.

Ito A. , Tsao PS , Adimoolam S. , Kimoto M. , Ogawa T. , Cooke JP Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99: 3092-3095.

Stuhlinger MC , Tsao PS , Her JH , Kimoto M. , Balint RF , Cooke JP Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001; 104: 2569-2575.

Lin KY , Ito A. , Asagami T. , et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase . Circulation 2002; 106: 987-992

Creager MA , Gallagher SJ , Girerd XJ , Coleman SM , Dzau VJ , Cooke JP L-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992; 90: 1248-1253.

Wilson A. , Harada R. , Nair N. , Balasubramanian N. , Cooke JP L-Arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation 2007; 116: 188-195.

Von der Leyen HE , Gibbons GH , Morishita R. , et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci U S A 1995; 92: 1137-1141.

Chen C-H. , Budas GR , Churchill EN , Disatnik MH , Hurley TD , Mochly-Rosen D. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart . Science 2008; 321: 1493-1495.

Wang Y. , Monzingo AF , Hu S. , Schaller TH , Robertus JD , Fast W. Developing dual and specific inhibitors of dimethylarginine dimethylaminohydrolase-1 and nitric oxide synthase: toward a targeted polypharmacology to control nitric oxide. Biochemistry 2009; 48: 8624-8635.